Your browser doesn't support javascript.
loading
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.
Kobayashi, Masamitsu; Kako, Jun; Iba, Arisa; Okuyama, Ayako; Ozawa, Keiko; Abe, Masakazu; Wada, Makoto; Akechi, Tatsuo; Iihara, Hirotoshi; Imamura, Chiyo K; Kim, Yong-Il; Sasaki, Hidenori; Satomi, Eriko; Takeda, Masayuki; Tanaka, Ryuhei; Nakajima, Takako Eguchi; Nakamura, Naoki; Nishimura, Junichi; Noda, Mayumi; Hayashi, Kazumi; Higashi, Takahiro; Boku, Narikazu; Matsumoto, Koji; Matsumoto, Yoko; Okita, Kenji; Yamamoto, Nobuyuki; Aogi, Kenjiro; Iino, Keiko.
Afiliação
  • Kobayashi M; Graduate School of Nursing Science, St. Lukes International University, 10-1 Akashi-Cho, Chuo-Ku, Tokyo, 104-0044, Japan. kobayashi.masamitsu.at@slcn.ac.jp.
  • Kako J; Graduate School of Medicine, Mie University, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan.
  • Iba A; Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
  • Okuyama A; Graduate School of Nursing Science, St. Lukes International University, 10-1 Akashi-Cho, Chuo-Ku, Tokyo, 104-0044, Japan.
  • Ozawa K; Division of Survivorship Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
  • Abe M; Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
  • Wada M; Department of Psycho­Oncology and Palliative Medicine, Osaka International Cancer Institute, 3-1-69, Chuo-Ku, Osaka, 541-8567, Japan.
  • Akechi T; Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
  • Iihara H; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
  • Imamura CK; Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan.
  • Kim YI; Division of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-Ku, Osaka, Osaka, 533-0024, Japan.
  • Sasaki H; Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
  • Satomi E; Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan.
  • Takeda M; Department of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
  • Tanaka R; Department of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
  • Nakajima TE; Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara-Cho, Shogoin, 606-8507, Japan.
  • Nakamura N; Department of Radiation Oncology, St. Marianna University, 2-16-1, SugaoKawasaki, Miyamae, 216-8511, Japan.
  • Nishimura J; Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Osaka, 541-8567, Japan.
  • Noda M; Non-Profit Organizaition Sasaeau-Kai Alpha, 518-7 Kawado-Cho, Chuo-Ku, Chiba, Chiba, 260-0802, Japan.
  • Hayashi K; Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinnbashi Minatoku, Tokyo, 105-8461, Japan.
  • Higashi T; Department of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
  • Boku N; Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4-6-1 Shiroganedai, Minato-Ku, Tokyo, 108- 8639, Japan.
  • Matsumoto K; Division of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-Cho, Akashi, Hyogo, 673-0021, Japan.
  • Matsumoto Y; Non-Profit Organization Ehime Cancer Support Orange-No-Kai, 3-8-24 Furukawaminami, Matsuyama, Ehime, 790-0943, Japan.
  • Okita K; Department of Surgery, Otaru Ekisaikai Hospital, 1-4-1, Inaho, Otaru, Hokkaido, 047-0032, Japan.
  • Yamamoto N; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641-8509, Japan.
  • Aogi K; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan.
  • Iino K; School of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
Int J Clin Oncol ; 29(7): 889-898, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38722486
ABSTRACT

BACKGROUND:

Anticipatory chemotherapy-induced nausea and vomiting (CINV) is a conditioned response influenced by the severity and duration of previous emetic responses to chemotherapy. We aimed to evaluate the efficacy of non-pharmacologic interventions for anticipatory CINV among patients with cancer.

METHODS:

We conducted a systematic search in databases, including PubMed, the Cochrane Library, CINAHL, and Ichushi-Web, from January 1, 1990, to December 31, 2020. Randomized controlled trials, non-randomized designs, observational studies, or case-control studies that utilized non-pharmacological therapies were included. The primary outcomes were anticipatory CINV, with an additional investigation into adverse events and the costs of therapies. The risk-of-bias for each study was assessed using the Cochrane risk-of-bias tool, and meta-analysis was performed using Revman 5.4 software.

RESULTS:

Of the 107 studies identified, six met the inclusion criteria. Three types of non-pharmacological treatments were identified systematic desensitization (n = 2), hypnotherapy (n = 2), and yoga therapy (n = 2). Among them, systematic desensitization significantly improved anticipatory CINV as compared to that in the control group (nausea risk ratio [RR] = 0.60, 95% confidence interval [CI] = 0.49-0.72, p < 0.00001; vomiting RR = 0.54, 95% CI = 0.32-0.91, p = 0.02). However, heterogeneity in outcome measures precluded meta-analysis for hypnotherapy and yoga. Additionally, most selected studies had a high or unclear risk of bias, and adverse events were not consistently reported.

CONCLUSIONS:

Our findings suggest that systematic desensitization may effectively reduce anticipatory CINV. However, further research is warranted before implementation in clinical settings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Náusea / Neoplasias / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Náusea / Neoplasias / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article